| Vol. 11.44 – 8 December, 2020 |
| |
|
|
| In vitro pancreatitis induction by supraphysiological cholecystokinin (CCK) or ethanol plus low-dose CCK were used to assess SNAP23-KD effects on exocytosis and autophagy. [Autophagy] |
| |
|
|
PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
| Investigators showed that FURIN was highly expressed in human islets, while proprotein convertase that potentially could provide redundancy were expressed at considerably lower levels. [Diabetes] |
|
|
|
| In vitro BrdU proliferation and Annexin V cell death analyses were performed on PANC-1 and MIA PaCa-2 PDAC cell lines exposed to conditioned medium of different macrophage subsets. [BMC Cancer] |
|
|
|
| Treatment with clusterin remarkably upregulated microtubule-associated protein 1-light chain 3 (LC3)-II conversion in a dose and time-dependent manner with a significant increase in the autophagy-related 3 gene expression level, which is a mediator of LC3-II conversion. [Endocrinology and Metabolism] |
|
|
|
| Researchers used immunofluorescence confocal and immunofluorescence microscopy, immunohistochemistry, RT-qPCR, Western blotting, pharmacology, electrophysiology and insulin secretory studies in normal human, rat and mouse islets. [PLoS One] |
| |
|
|
| To generate spatially-resolved tumor and immune cell data at single cell resolution, investigators developed two quantitative multiplex immunofluorescence assays to interrogate myeloid cells and macrophages in the pancreatic ductal carcinoma tumor microenvironment. [Clinical Cancer Research] |
|
|
|
| Afatinib alone or in combination with gemcitabine decreased stemness and tumorspheres by reducing phosphorylation of EGFR family proteins, ERK, FAK, and cancer stem cell (CSC) markers. Mechanistically, afatinib treatment decreased CSC markers by downregulating SOX9 via FOXA2. [Oncogene] |
|
|
|
| Subcutaneous allograft tumors with overexpression or knock-down of vascular cell adhesion molecule-1 (VCAM-1), as well as VCAM-1-blocking treatment in the spontaneous mouse model of pancreatic cancer, revealed that sVCAM-1 promoted tumor growth and resistance to gemcitabine treatment in vivo but not in vitro. [Scientific Reports] |
| |
|
|
|
| Scientists discuss nerve fiber crosstalk with the main different components of the tumor microenvironment, the immune cells, and the fibroblasts. They also discuss the crosstalk between the nerve fibers and the cancer. [Oncogene] |
|
|
|
| The authors discuss the role of the MET/hepatocyte growth factor (HGF) axis in tumor progression and dissemination of pancreatic cancer. Therapeutic approaches that were developed targeting either the ligand or the receptor have not been shown to translate well into clinical settings. [International Journal of Molecular Sciences] |
|
|
|
|
| AB Science SA announced that its Phase III study met its primary objective to demonstrate increase in survival in pancreatic cancer with pain. Study AB12005 evaluated masitinib 6.0 mg/kg/day in combination with gemcitabine in first-line treatment of unresectable locally advanced or metastatic pancreatic cancer patients with pain. [Nature Reviews Drug Discovery] |
|
|
|
| Henry Ford Health System announced a $16 million gift to its Henry Ford Pancreatic Cancer Center, which was launched in 2018 by an initial $20 million gift from the same donor, who wishes to remain anonymous. The gift will bolster the HFPCC’s clinical and translational research endeavors in the fight against this devastating disease, for which the five-year survival rate is only 9%. [Henry Ford Health System] |
|
|
|
|
| January 15 – 16, 2021 Virtual |
|
|
|
|
|
| University of Cincinnati – Cincinnati, Ohio, United States |
|
|
|
| NIH National Cancer Institute – Bethesda, Maryland, United States |
|
|
|
| Harvard Joslin Diabetes Center – Boston, Massachusetts, United States |
|
|
|
| University of Michigan – Ann Arbor, Michigan, United States |
|
|
|
| Stanford University – Stanford, California, United States |
|
|
|
|